LBPH News and Press, Longboard Pharmaceuticals Inc. From 05/05/22

Longboard Pharmaceuticals press release (NASDAQ:LBPH): Q1 GAAP EPS of -$0.56. At March 31, 2022, Longboard’s cash, cash equivalents and short-term investments were approximately $96.1 million. Our cash position is expected to support operations into 2024 based on our current business p...

Phase 1 data for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies, presented at the American Academy of Neurology (AAN) Annual Meeting Initiated Phase 1b/2a PACIFIC Study evaluating LP352 for participants with developmental and epi...

Two poster presentations highlight Phase 1 data for LP352 in healthy volunteers SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for ...

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will parti...

SAN DIEGO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard’s President...

Longboard Pharmaceuticals (NASDAQ:LBPH) appointed Randall Kaye as chief medical officer. Philip Perera has retired as medical chief while remaining with LBPH in an advisory role. Kaye has over 30 years of experience in the medical field. Prior to joining Longboard, he served as chief medical ...

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Dr. Randall Kaye as Chief Medical ...

Longboard Pharmaceuticals press release (NASDAQ:LBPH): FY GAAP EPS of -$1.93. FY Net loss $27.80M For further details see: Longboard Pharmaceuticals GAAP EPS of -$1.93

Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs) LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndr...

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will presen...